Show simple item record

dc.contributor.authorVasudeva K.
dc.contributor.authorBalyan R.
dc.contributor.authorMunshi A.
dc.date.accessioned2020-01-31T11:33:59Z
dc.date.available2020-01-31T11:33:59Z
dc.date.issued2019
dc.identifier.issn15351084
dc.identifier.urihttp://kr.cup.edu.in/handle/32116/2558
dc.description.abstractStroke is the second largest cause of death worldwide. Angiotensin converting enzyme (ACE) gene has emerged as an important player in the pathogenesis of hypertension and consequently stroke. It encodes ACE enzyme that converts the inactive decapeptide angiotensin I to active octapeptide, angiotensin II (Ang II). Dysregulation in the expression of ACE gene, on account of genetic variants or regulation by miRNAs, alters the levels of ACE in the circulation. Variable expression of ACE affects the levels of Ang II. Ang II acts through different signal transduction pathways via various tyrosine kinases (receptor/non-receptor) and protein serine/threonine kinases, initiating a downstream cascade of molecular events. In turn these activated molecular pathways might lead to hypertension and inflammation thereby resulting in cardiovascular and cerebrovascular diseases including stroke. In order to regulate the overexpression of ACE, many ACE inhibitors and blockers have been developed, some of which are still under clinical trials.en_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.subjectGenetic variantsen_US
dc.subjectGlial cellsen_US
dc.subjectmiRNAsen_US
dc.subjectNeuronsen_US
dc.subjectStrokeen_US
dc.subjectVascular smooth muscle cellsen_US
dc.titleACE-Triggered Hypertension Incites Stroke: Genetic, Molecular, and Therapeutic Aspectsen_US
dc.typeReviewen_US
dc.identifier.doi10.1007/s12017-019-08583-1
dc.identifier.urlhttps://link.springer.com/article/10.1007%2Fs12017-019-08583-1
dc.title.journalNeuroMolecular Medicineen_US
dc.type.accesstypeClose Accessen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record